Back

Sex differences in excess risk of cardiovascular disease and mortality among patients with type 2 diabetes: a matched register-based cohort study

30 August 2026 (09:09 - 09:27)
Organised by: Logo
Congress Presentation Part of: Cardio-renal-metabolic syndrome: the triple threat Diabetes and the Heart ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Associate Professor Christina Lundberg

Institute of Medicine - Sahlgrenska Academy - University of Gothenburg, Gothenburg (Sweden)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on cardio-renal-metabolic syndrome
Professor N. Marx (Aachen, DE)
Slides Video
Presentation thumbnail
Cardiovascular risk emerges below the diagnostic threshold for diabetes: insights from the Western Denmark Heart Registry
Doctor K. Olesen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Association of clonal hematopoiesis with cardiovascular-kidney-metabolic syndrome in 434,000 individuals
Ms A. Chang (US)
Abstract Slides Video
Presentation thumbnail
Risk-based thresholds enable efficient allocation of GLP-1 receptor agonists in atherosclerotic cardiovascular disease without diabetes
Doctor S. Hageman (Utrecht, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-renal-metabolic syndrome: the triple threat
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 09:09 CET
You may be interested in
thumbnail
Congress Presentation
Timing, clustering, mortality, sex differences of CVD
31 August 2025
thumbnail
Congress Presentation
Incident cardiovascular disease in women with type 1 or type 2 diabetes by history of hypertensive disorders of pregnancy
25 August 2023
thumbnail
Congress Presentation
Real-life use of novel glucose lowering agents after acute myocardial infarction and stable coronary artery disease in patients with diabetes - experience from national use in the SWEDEHEART-registry
26 August 2023
thumbnail
Congress Presentation
Sex differences in indications, complications and outcomes of de novo implantable cardioverter defibrillator and cardiac resynchronization therapy: with a focus on diabetes status
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources